MC# 23-06
First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
MC# 22-42
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase I Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
Bringing Cancer Clinical Trial Information to the Palm of Your Hand
Mary Crowley Cancer Research is a specialized clinical research center that offers access to new investigational therapies through the administration of Phase I and II clinical trials. Our approach is to rapidly advance the discovery of potential new therapies and positively impact the care of cancer patients in their lifetime.
Personalized approach to cancer research
Clinical trials are matched to molecular information found within each cancer patient
Qualified Physician Investigators add to the understanding of what drives cancer and create innovative research applications that attack these drivers
Patient-centric focus brings the newest clinical trial options to patients at a rapid pace
